Literature DB >> 2970331

When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans?

L S Freedman1, P Workman.   

Abstract

We describe a simple and rapid method to determine the amount by which the area under the curve (AUC) is underestimated when a drug is given by i.v. infusion, but the infusion period is ignored and the post-infusion data are analysed as if they derive from a bolus injection. Charts are provided that allow the investigator to determine the approximate underestimation for drugs following the one- and two-compartment models, and hence to decide whether it is acceptable to ignore the infusion period in a given case (e.g., underestimation less than 5% or 10%). Equations are also provided that allow the exact underestimation to be calculated, together with the true value of the AUC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970331     DOI: 10.1007/bf00257304

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.

Authors:  H F Newman; N M Bleehen; P Workman
Journal:  Br J Radiol       Date:  1986-04       Impact factor: 3.039

2.  Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. EORTC Pharmacokinetics and Metabolism Group.

Authors: 
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

3.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

4.  Potential roles for preclinical pharmacology in phase I clinical trials.

Authors:  J M Collins; D S Zaharko; R L Dedrick; B A Chabner
Journal:  Cancer Treat Rep       Date:  1986-01
  4 in total
  12 in total

1.  Renal handling of carboplatin.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; J T Nielsen; L S Andersen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  A limited sampling method for estimation of the etoposide area under the curve.

Authors:  A S Strömgren; B T Sørensen; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.

Authors:  M H Bronchud; J M Margison; A Howell; M Lind; S B Lucas; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man.

Authors:  P Workman; H F Newman; N M Bleehen; R Ward; C E Smithen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.

Authors:  P Jakobsen; E Steiness; L Bastholt; M Dalmark; A Lorenzen; D Petersen; S B Gjedde; E Sandberg; C Rose; O S Nielsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; B Melotti; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.

Authors:  N A Dobbs; C J Twelves; H Gillies; C A James; P G Harper; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.

Authors:  N A Dobbs; C J Twelves; P Rizzi; J D Warwick; E M Metivier; R Williams; P J Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.